RK
Roshan Kumar
Translational Health Science and Technology Institute, University of Eastern Finland, Maharshi Dayanand University, Ark Therapeutic Oy
0000-0002-8797-8620
About
Interested in understanding role of SGLT2 in diabetes. Screening drug molecules against SGLT2 to identify drug molecules to be useful in treating diabetes
Understanding role of fatty acid transporter protein 5 in Non alcohlic fatty liver disease. To identify drug molecules inhibiting FATP5 receptor in HepG2 and Huh7 cells as potential therapeutic drug for NAFLD.
Understanding antimicrobial resistance in Vibrio cholerae and screening drug molecules which can reduce antimicrobial resistance and act as therapeutic drug for controlling vibrio cholerae pathogenesis
Employment
-
Translational Health Science and Technology Institute lab Technician2021 - Present
-
Translational Health Science and Technology Institute Senior Technical officer2019 - 2021
-
Translational Health Science and Technology Institute Technical Assistant2014 - 2019
-
University of Eastern Finland Research Graduate2011 - 2014
-
Ark Therapeutic Oy Research Graduate2008 - 2011
Education
-
University of Eastern Finland M.Sc (Master of Science) Biotechnology & Molecular Medicine2008 - 2010
-
Maharshi Dayanand University B.E. (Bachelor of Engineering) Biotechnology2002 - 2006
Projects & Funding
Projects & funding information is unavailable.
Publications (4)
- Correction: Knockdown of SCN5A alters metabolic-associated genes and aggravates hypertrophy in the cardiomyoblast Save
- Knockdown of SCN5A alters metabolic-associated genes and aggravates hypertrophy in the cardiomyoblast Save
- Synthesis of Benzyl C -Analogues of Dapagliflozin as Potential SGLT2 Inhibitors Save
- Musa balbisiana Fruit Rich in Polyphenols Attenuates Isoproterenol-Induced Cardiac Hypertrophy in Rats via Inhibition of Inflammation and Oxidative Stress Save